Enlightened Opinion

Partners4Access > Enlightened Opinion

Innovative Access Agreements: A potential payer solution for Cell & Gene Therapies

innovative-access-agreements-a-potential-payer-solution-for-cell-gene-therapies

A US and EU perspective By Daniele Severi Bruni & Sophie Schmitz What’s the idea? Payer concerns over increasing cost of therapies and uncertainty of clinical data has led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). […]

Read More

Webinar 2: U.S. lessons learnt from Kymriah & Luxturna

In the second of three webinars, P4A is focussing on the US environment for gene therapies. Single application cell and gene therapies in the US face health insurance challenges driven by a short-term focus, disconnection between price reporting and outcomes value, and complex distribution models…

Read More

Conferences

In our mission to understand and influence the debate on Orphan Drugs, P4A will be closely following industry and scientific conferences including attending some of them.

All Rights Reserved ©   Privacy   Partners 4 Access 2018